Pahr Therapeutics is a clinical stage business, is to create innovative ways to treat pulmonary arterial hypertension.
Pahr Therapeutics has raised $14.0M in total funding. The most recent round was Seed. The last funding was announced in July 2025.
Pahr Therapeutics's investors include RA Capital Management, UTEC - The University of Tokyo Edge Capital Partners, AN Ventures.
Pahr Therapeutics is headquartered in Boston, United States.
Pahr Therapeutics is a clinical stage business, is to create innovative ways to treat pulmonary arterial hypertension.
Pahr Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pahr Therapeutics — Funding & Investors." VCBacked, July 28, 2025, https://www.vcbacked.co/company/pahr-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Pahr Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/pahr-therapeutics
{{cite web |title=Pahr Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pahr-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated